Title : The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study.

Pub. Date : 2016 Jul

PMID : 26207797






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 +- 7.84 nmol PO4), placebo, 304.12 +- 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 +- 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 +- 33.50 nmol PO4 (P < 0.002). po4 ATP synthase F1 subunit epsilon Homo sapiens
2 Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 +- 7.84 nmol PO4), placebo, 304.12 +- 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 +- 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 +- 33.50 nmol PO4 (P < 0.002). po4 ATP synthase F1 subunit epsilon Homo sapiens
3 Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 +- 7.84 nmol PO4), placebo, 304.12 +- 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 +- 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 +- 33.50 nmol PO4 (P < 0.002). po4 ATP synthase F1 subunit epsilon Homo sapiens
4 Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 +- 7.84 nmol PO4), placebo, 304.12 +- 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 +- 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 +- 33.50 nmol PO4 (P < 0.002). po4 ATP synthase F1 subunit epsilon Homo sapiens